Skip to main content
Aurobindo Pharma Ltd. logo

Aurobindo Pharma Ltd. — Investor Relations & Filings

Ticker · AUROPHARMA ISIN · INE406A01037 LEI · 335800G4T2A353RDGM23 BSE.NS Manufacturing
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS AUROPHARMA

About Aurobindo Pharma Ltd.

https://www.aurobindo.com/

Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.

Recent filings

Filing Released Lang Actions
Intimation of incorporation of a new stepdown subsidiary in France.
Regulatory Filings Classification · 82% confidence The document is a statutory disclosure under Regulation 30 of SEBI listing rules, notifying stock exchanges of the incorporation of a wholly-owned step-down subsidiary and providing details of share subscription and capital. It is not a full financial report, management presentation, dividend notice, or proxy. It is a routine regulatory announcement under listing obligations and best fits the generic Regulatory Filings (RNS) category.
2026-05-22 English
Acquisition
Regulatory Filings Classification · 94% confidence The document is a compliance announcement under Regulation 30 of the SEBI (LODR) Regulations notifying the exchange of incorporation of a new wholly owned subsidiary. It is a regulatory disclosure to the stock exchanges, not a full financial report, earnings release, or corporate governance document. It fits the general category of a regulatory filing/disclosure announcement. Therefore, it is classified as RNS (Regulatory Filings).
2026-05-22 English
Submission of the Financial Results for the year ended March 31, 2026
Interim / Quarterly Report Classification · 86% confidence The document is a board-approved publishing of the Company’s Audited Financial Results under SEBI Reg.33, containing full standalone and consolidated statements (P&L, Balance Sheet, Cash Flows) and notes for the quarter and year ended March 31, 2026. It is not merely a summary highlights release (so not ER), nor a full Annual Report package (no MD&A, corporate overview chapters), nor a simple publication announcement (RPA). It is a comprehensive interim/quarterly results filing with substantive financial data and thus falls under “Interim / Quarterly Report” (IR). FY 2026
2026-05-21 English
Appointment
Regulatory Filings Classification · 78% confidence The document is a stock exchange filing under SEBI Listing Regulations notifying the re-appointment of the company’s internal auditor. It is not a financial report nor a proxy statement, nor a management discussion, but a regulatory compliance announcement relating to corporate governance disclosures. It does not contain financial statements or financial data and serves to inform the exchanges of a Board decision. This fits the ‘Regulatory Filings’ (RNS) category as a general compliance announcement.
2026-05-21 English
Intimation of re-appointment of Internal Auditor.
Regulatory Filings Classification · 98% confidence The document is a formal notification under SEBI Listing Regulations of the re-appointment of the company’s internal auditor. It does not contain financial results or statements, nor is it the text of an audit report. It is not a board member or senior management change, nor a dividend, share issue, or legal update. It is a routine regulatory disclosure under Listing Rule 30, serving as a compliance announcement to stock exchanges. Therefore, it falls under the catch-all category for miscellaneous regulatory announcements (RNS).
2026-05-21 English
Intimation of appointment of RPR & Associates as Secretarial Auditor of the Company.
Regulatory Filings Classification · 91% confidence The document is a stock exchange disclosure under SEBI Listing Obligation Regulation 30 announcing the resignation and appointment of the company’s secretarial auditors. It is not the actual audit report itself (AR), nor a board director or senior management change (MANG) since secretarial auditors are external auditors, not board or management members, and the document is a compliance announcement. As such, it falls into the general regulatory announcement category (RNS).
2026-05-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.